tiprankstipranks
Trending News
More News >
Infinity Pharmaceuticals, Inc. (INFIQ)
:INFIQ
US Market
Advertisement

Infinity Pharmaceuticals (INFIQ) Price & Analysis

Compare
918 Followers

INFIQ Stock Chart & Stats

<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)

INFIQ FAQ

What was Infinity Pharmaceuticals, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Infinity Pharmaceuticals, Inc.’s market cap?
Currently, no data Available
When is Infinity Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Infinity Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is Infinity Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Infinity Pharmaceuticals, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
    Does Infinity Pharmaceuticals, Inc. pay dividends?
    Infinity Pharmaceuticals, Inc. does not currently pay dividends.
    What is Infinity Pharmaceuticals, Inc.’s EPS estimate?
    Infinity Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Infinity Pharmaceuticals, Inc. have?
    Currently, no data Available
    What happened to Infinity Pharmaceuticals, Inc.’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Infinity Pharmaceuticals, Inc.?
    Currently, no hedge funds are holding shares in INFIQ

    Company Description

    Infinity Pharmaceuticals, Inc.

    Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.

    Infinity Pharmaceuticals (INFIQ) Earnings & Revenues

    Similar Stocks
    Company
    Price & Change
    Follow
    Biodexa Pharmaceuticals
    Salarius Pharmaceuticals
    Processa Pharmaceuticals
    GRI Bio
    Onconetix

    Ownership Overview

    0.03%99.97%
    Insiders
    Mutual Funds
    0.03% Other Institutional Investors
    99.97% Public Companies and
    Individual Investors

    Options Prices

    Currently, No data available
    ---
    Popular Stocks
    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis